Mercator Medical SA

As of March 31, 2026, Mercator Medical SA carries a market capitalization of 109.01M, placing it among publicly traded companies globally. Its enterprise value stands at 65.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mercator Medical SA's next confirmed earnings release is scheduled for November 30, 2026.

As of March 31, 2026, Mercator Medical SA has 9.14M shares outstanding.

As of March 31, 2026, Mercator Medical SA trades at a trailing price-to-earnings ratio of 39.34. The price-to-sales ratio is 0.82, and the price-to-book ratio stands at 0.51.

As of March 31, 2026, Mercator Medical SA trades at an EV/EBITDA multiple of 8.87 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 161.81 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Mercator Medical SA trades at an EV/FCF ratio of 18.60, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 65.92M versus a market cap of 109.01M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Mercator Medical SA maintains a current ratio of 5.10, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.50, indicating elevated leverage, while an interest coverage ratio of 40.65 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Mercator Medical SA posted a return on equity (ROE) of 1.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.12 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.16, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.37, useful for judging operating efficiency across full business cycles. The company generates approximately 149,737.70 in revenue per employee across its workforce of 891.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.93 indicates how many times Mercator Medical SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Mercator Medical SA recorded 1.63M in income tax expense. That works out to an effective tax rate of 37.45, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.35M, leaving 2.79M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Mercator Medical SA's stock has gained approximately 40.34% over the past 52 weeks. The 50-day moving average sits at 13.28, while the 200-day moving average is 11.87.

Over the twelve months ended March 31, 2026, Mercator Medical SA generated 133.49M in revenue and converted that into 2.79M in net income, yielding earnings per share of 0.30. EBITDA reached 7.43M, while operating income came in at -743,318.09.

As of March 31, 2026, Mercator Medical SA holds 47.64M in cash and equivalents against 5.33M in total debt, resulting in a net debt position of -35.81M. Total book value stands at 214.19M, with working capital of 93.75M providing operational flexibility.

Mercator Medical SA produced 16.43M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -13.00M in capital expenditures, free cash flow totaled 3.43M - equivalent to 0.37 per share.

Over the twelve months ended March 31, 2026, Mercator Medical SA posted a gross margin of 30.27, reflecting its pricing power and cost economics. The operating margin of -0.56 and net profit margin of 2.09 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 3.13, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.21, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Mercator Medical SA shareholders.

As of March 31, 2026, Mercator Medical SA has an Altman Z-Score of 4.50, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.